Australia - English - Department of Health (Therapeutic Goods Administration)

aubex pharma pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: hydrogenated vegetable oil; purified water; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; magnesium stearate - bpa-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although bpa-flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, bpa-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of bpa-flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,bpa-flecainide tablets are used for continuous maintenance of normal rhythm follo

Australia - English - Department of Health (Therapeutic Goods Administration)

aubex pharma pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; magnesium stearate; microcrystalline cellulose; hydrogenated vegetable oil; purified water; croscarmellose sodium - bpa-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although bpa-flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, bpa-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of bpa-flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,bpa-flecainide tablets are used for continuous maintenance of normal rhythm follo

Canada - English - Health Canada

marcan pharmaceuticals inc - flecainide acetate - tablet - 50mg - flecainide acetate 50mg - class ic antiarrythmics

Canada - English - Health Canada

marcan pharmaceuticals inc - flecainide acetate - tablet - 100mg - flecainide acetate 100mg - class ic antiarrythmics

Canada - English - Health Canada

nora pharma inc - flecainide acetate - tablet - 50mg - flecainide acetate 50mg

Canada - English - Health Canada

nora pharma inc - flecainide acetate - tablet - 100mg - flecainide acetate 100mg

Canada - English - Health Canada

auro pharma inc - flecainide acetate - tablet - 50mg - flecainide acetate 50mg - class ic antiarrythmics

Canada - English - Health Canada

auro pharma inc - flecainide acetate - tablet - 100mg - flecainide acetate 100mg - class ic antiarrythmics

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: magnesium stearate; silicified microcrystalline cellulose; croscarmellose sodium; maize starch - apo-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, apo-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,apo-flecainide tablets are used for continuous maintenance of normal rhyt

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: magnesium stearate; maize starch; silicified microcrystalline cellulose; croscarmellose sodium - apo-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, apo-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,apo-flecainide tablets are used for continuous maintenance of normal rhyt